Safety and Feasibility of Transendocardial Autologous Bone Marrow Cell Transplantation in Patients With Advanced Heart Disease

Fuchs, Shmuel; Kornowski, Ran; Weisz, Giora; Satler, Lowell F.; Smits, Peter; Okubagzi, Petros; Baffour, Richard; Aggarwal, Anita; Weissman, Neil J.; Cerqueira, Manuel D.; Waksman, Ron; Serrruys, Parrick; Battler, Alexander; Moses, Jeffrey W.; Leon, Martin B.; Epstein, Stephen E.

doi:10.1016/j.amjcard.2005.09.132

Cited by 122 publications

(90 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparable observations have been observed in similarly designed trials performed by other groups (Beeres et al 2006;Fuchs et al 2006). The non-randomized nature of these trials prohibits fi rm conclusions to be made about the efficacy of BMMNC injection in these patients.…”

Section: Chronic Coronary Ischemiasupporting

confidence: 68%

“…The non-randomized nature of these trials prohibits fi rm conclusions to be made about the efficacy of BMMNC injection in these patients. One important observation has been the great diversity in the functional properties of BMCs taken from different patients (Fuchs et al 2006). This is a well-known phenomenon that emphasizes the limitations of autologous BMC therapy, especially in elderly patients and those with severe, chronic illness (Heeschen et al 2004).…”

Section: Chronic Coronary Ischemiamentioning

confidence: 99%

See 1 more Smart Citation

Cellular Therapy for Cardiovascular Disease Part 2—Delivery of Cells and Clinical Experience

Psaltis

Gronthos

Worthley

et al. 2008

Clinical medicine. Cardiology

View full text Add to dashboard Cite

Section: Chronic Coronary Ischemiasupporting

confidence: 68%

Section: Chronic Coronary Ischemiamentioning

confidence: 99%

Cellular Therapy for Cardiovascular Disease Part 2—Delivery of Cells and Clinical Experience

Psaltis

Gronthos

Worthley

et al. 2008

Clinical medicine. Cardiology

View full text Add to dashboard Cite

“…Endoventricular catheter-based delivery methods have been employed to transplant BM-SCs in selected patients. Fuchs et al successfully transplanted BM-SCs in 10 patients using a catheter-based endoventricular injection technique guided by electromechanical mapping to identify areas of ischemia [86]. Three-month follow-up did not demonstrate any statistically significant differences in objective indices of myocardial function or perfusion, and these findings call into question whether a sufficient volume of cells was transplanted into the myocardium.…”

Section: Cellular Therapymentioning

confidence: 97%

Surgical aspects of congestive heart failure

2006

View full text Add to dashboard Cite

Despite tremendous advances in the medical management of congestive heart failure the gold standard for the treatment of end stage congestive heart failure remains cardiac transplantation. The acknowledged critical limitation of sufficient suitable organ donors has resulted in the refinement and development of novel surgical alternatives for the treatment of congestive heart failure. These approaches include the extension of current conventional cardiac operations such as mitral valve repair to the failing ventricle, surgically reconstructing the size and shape of the failing left ventricle in order to optimize geometry and render it a more efficient pump, and partial or complete replacement of the ventricle with a mechanical device. The continued evolution of such therapies is likely to one day have a significant epidemiologic impact on patients suffering from end stage heart failure.

show abstract

“…Dramatic advancements in the past decade in the fields of vascular and developmental biology have led to the characterization of multiple cell types with angiogenic and/or myogenic potential, including bone marrow cells (BMC), which have been investigated for the treatment of ischemic heart disease [2,3,4,5]. In patients undergoing coronary artery bypass, BMC transplantation into ischemic myocardium was effective in restoring cardiac function [6,7,8,9,10,11,12], though the benefits were not observed in all cases [13].…”

Section: Introductionmentioning

confidence: 99%

Effect of Autologous Bone Marrow Cell Transplantation Combined with Off-Pump Coronary Artery Bypass Grafting on Cardiac Function in Patients with Chronic Myocardial Infarction

Wang

Jiang

et al. 2014

Cardiology

View full text Add to dashboard Cite

Objectives: This study aimed to investigate the feasibility and effects of intramuscular injections of autologous bone marrow cells (BMC) combined with off-pump coronary artery bypass grafts (OPCAB) on improving cardiac function in chronic myocardial infarction patients. Methods: Ninety patients with chronic myocardial infarction were prospectively enrolled and randomized to an OPCAB with saline or an OPCAB with BMC-treatment group. After finishing CABG, patients received injections of BMC or saline into the marginal area of the infarct. The primary endpoint was incidence of emergent adverse events within 6 months. Results: There were no differences between the control and BMC-treated groups in baseline ejection fractions (EF) or wall motion score indices (WMSI) in the affected segments. At the 6-month follow-up, the ejection fraction was significantly increased in the BMC-treated group compared to controls (47.58 w 6.34 vs. 40.11 w 7.42; p < 0.05), whereas the WMSI were significantly decreased (1.25 w 0.32 vs. 1.54 w 0.53; p < 0.05), with no occurrences of life-threatening arrhythmias or death. The addition of BMC injections to OPCAB treatment increased regional perfusion to the marginal infarct area. Conclusion: These results demonstrate that BMC transplant is beneficial to the cardiac function with no adverse effects, and therefore a safe and feasible adjunct therapy providing beneficial effects in clinical practice. i 2014 S. Karger AG, Basel

show abstract

Safety and Feasibility of Transendocardial Autologous Bone Marrow Cell Transplantation in Patients With Advanced Heart Disease

Cited by 122 publications

References 20 publications

Cellular Therapy for Cardiovascular Disease Part 2—Delivery of Cells and Clinical Experience

Cellular Therapy for Cardiovascular Disease Part 2—Delivery of Cells and Clinical Experience

Surgical aspects of congestive heart failure

Effect of Autologous Bone Marrow Cell Transplantation Combined with Off-Pump Coronary Artery Bypass Grafting on Cardiac Function in Patients with Chronic Myocardial Infarction

Contact Info

Product

Resources

About